Investment Thesis
MAIA is a pre-revenue biotech company in severe financial distress with zero cash reserves and negative operating cash burn of $5.3M. The combination of no revenue, depleted cash position, and mounting operating losses creates an existential liquidity crisis that requires immediate capital infusion or asset sales to remain viable.
Strengths
- No debt obligations limiting financial flexibility
- Positive stockholders' equity of $27.8M provides some asset base
- Recent insider activity suggests management engagement despite challenges
Risks
- Critical cash position: $0.00 reported with negative quarterly burn of $5.3M threatens immediate solvency
- No revenue generation despite apparent commercial stage, indicating failed market adoption or development setback
- Negative ROE (-22.9%) and ROA (-18.0%) indicate shareholder value destruction and asset inefficiency
- Unsustainable cash burn rate: at current pace, company has minimal runway absent emergency financing
Key Metrics to Watch
- Cash position and runway to next financing milestone
- Quarterly cash burn trend and path to profitability
- Revenue generation from any clinical or commercial pipeline advancement
Financial Metrics
Revenue
0.0
Net Income
-6.4M
EPS (Diluted)
$-0.14
Free Cash Flow
-5.3M
Total Assets
35.3M
Cash
0.0
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-22.9%
ROA
-18.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
5.59x
Quick Ratio
5.59x
Debt/Equity
0.00x
Debt/Assets
21.4%
Interest Coverage
-121,928.58x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T08:14:43.676099 |
Data as of: 2026-03-31 |
Powered by Claude AI